← Russell 3000 cross-section

ADMA ADMA BIOLOGICS, INC.

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Healthcare

Scale

Market cap
$2.1bn
Revenue TTM
$512m
Net income TTM
$169m
Free cash flow
$116m
Composite score
71.3
Sector rank
#1610

Valuation

P / E
12.5
EV / EBITDA
9.4
EV / sales
4.2
FCF yield
5.50%
Earnings yield vs 10-yr
3.25pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
33.0%
EBITDA margin
45.3%
ROE
41.4%
ROIC
48.3%
Revenue growth
8.0%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

During the three and six months ended June 30, 2026 and 2025, comprehensive income was equal to the net income amounts presented for the respective periods in the accompanying condensed consolidated statements of operations. Revenue Recognition Revenues are comprised of (i) revenues from the sale of the Company’s immunoglobulin products, ASCENIV, BIVIGAM and Nabi-HB, (ii) product revenues from the sale of human plasma collected by the Company’s Plasma Collection Centers business segment, (iii) contract manufacturing and laboratory services revenue, (iv) revenues from the sale of intermediate by-products and (v) license and other revenues primarily attributable to the out-licensing of ASCENIV …ADMA BIOLOGICS, INC., 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →